Iso-osmolar agent shows higher renal failure rate

January 1, 2009 Diagnostic Imaging. Vol. 31 No. 1 Iso-osmolar agent shows higher renal failure rate Radiologists hoped the introduction of isoosmolar contrast media would eliminate severe adverse reactions to x-ray contrast. Alas, it was not to be. A large retrospective Swedish study identified a significantly higher rate of renal failure among patients administered iso-osmolar iodixanol (Visipaque) compared with patients who received low-osmolar ioxaglate (Hexabrix). Dr. Per Liss and colleagues at the University of Uppsala presented their evaluation of 23,224 patients at the 2008 RSNA meeting. They found that 1.7% of patients who received iodixanol developed primary or secondary renal failure within 12 months of administration. The 12-month renal failure rate for patients who received ioxaglate was 0.8%.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC